Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

Rhea-AI Summary

Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its participation in two upcoming investor conferences in September 2024. The company will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, at 12:30pm ET, and the 2024 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 17, at 8:35am ET.

Investors and interested parties can access live webcasts of these presentations through the 'Events' section of Lexicon's website at www.lexpharma.com/events. Recordings of the webcasts will remain available for two weeks following the original on-demand date, providing an opportunity for those unable to attend the live events to catch up on Lexicon's latest updates and strategic insights.

THE WOODLANDS, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lexicon management will participate in the following investor conferences taking place in September: 

• H.C. Wainwright 26th Annual Global Investment Conference – Tuesday, September 10, 2024 at 12:30pm ET 
  
  
• 2024 Cantor Fitzgerald Global Healthcare Conference – Tuesday, September 17, 2024 at 8:35am ET
  

A simultaneous webcast for these events will be available in the “Events” section of the Lexicon website at www.lexpharma.com/events and a recording of the webcast will be available for two weeks following the original on-demand date.

About Lexicon Pharmaceuticals 
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon is commercially launching one of these medicines, INPEFA^® (sotagliflozin) in the United States, and has a pipeline of other promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, diabetes and metabolism and other indications.  For additional information, please visit www.lexpharma.com. 

Safe Harbor Statement 

This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize INPEFA in heart failure on the timeline and/or at the prices currently contemplated or at all, conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin (in other indications), LX9211, LX9851 and its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2023 and other subsequent disclosure documents filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. 

For Media and Investor Inquiries: 

Lisa DeFrancesco  
Lexicon Pharmaceuticals, Inc.         
lexinvest@lexpharma.com  

FAQ

When is Lexicon Pharmaceuticals (LXRX) presenting at the H.C. Wainwright Global Investment Conference in 2024?

Lexicon Pharmaceuticals (LXRX) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024 at 12:30pm ET.

What time is Lexicon Pharmaceuticals (LXRX) speaking at the 2024 Cantor Fitzgerald Global Healthcare Conference?

Lexicon Pharmaceuticals (LXRX) is scheduled to speak at the 2024 Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 17, 2024 at 8:35am ET.

How can investors access Lexicon Pharmaceuticals' (LXRX) conference presentations in September 2024?

Investors can access live webcasts of Lexicon Pharmaceuticals' (LXRX) conference presentations through the 'Events' section of the company's website at www.lexpharma.com/events.

How long will recordings of Lexicon Pharmaceuticals' (LXRX) September 2024 conference presentations be available?

Recordings of Lexicon Pharmaceuticals' (LXRX) September 2024 conference presentations will be available for two weeks following the original on-demand date.